Positive final results of Randomised Controlled Trial on Quality of Life presented orally at ASCO 2025
For the 2nd consecutive year, the Randomised Controlled Trial (RCT) of our personalised patient support solutions has been presented orally at the annual meeting of the American Society of Clinical Oncology (ASCO).
After the presentation on interim results in 2024, this year the Trial’s final results were presented, highlighting the impact of our solution on cancer patients’ quality of life and healthcare costs.
Study design
The RCT included 200 patients diagnosed with advanced or metastatic non-small cell lung cancer (NSCLC) from 14 clinics. Patients were randomised into 2 arms through the CareAcross platform: those in the Intervention arm (A) would receive personalised support for each of their reported side-effects, while those in the Control arm (B) would receive general information only.
These Patient Reported Outcomes (PROs) allowed patients to report any of the 22 pre-selected side-effects. For each report, their treating clinician would receive a notification, and would also have ongoing access to the current and past reports via the platform’s Remote Patient Monitoring (RPM) component.
The primary endpoint of the study was improvements in Quality of Life and Adverse Events, measured through the above reports and the EQ-5D-5L questionnaire.
Improvements in patients’ quality of life and adverse events
The CareAcross solution helped cancer patients improve their side effects and quality of life (as measured by the EQ-5D-5L questionnaire).
More specifically:
- Among the 22 adverse events, 17 improved more in the Intervention arm (including 2 with statistical significance), 1 improved equally, and 4 improved more in the Control arm.
- Regarding the EQ-5D-5L responses, when compared with data at best response, Anxiety/Depression showed the biggest difference in improvement for the Intervention arm vs the Control arm.
Statistically significant reductions in healthcare costs
Beyond the important improvements in side effects and quality of life, patients on the Intervention arm of the CareAcross solution were associated with statistically significantly lower costs for hospitalisation and diagnostics.
More specifically:
- 41.6% reduction in hospitalisation costs (p<0.001).
- 72.3% reduction in diagnostics costs (p<0.001).
Important findings on the value of Patient Reported Outcomes (PROs)
Bringing the focus back on adverse events (AEs), it was found that there was a statistically significant difference between the number of patients who reported AEs on the CareAcross platform and those who reported via their clinicians (89% vs 68% of patients respectively, p<0.01).
This emphasises the value of Patient Reported Outcomes (PROs) and reinforces the importance of the patients’ perspective in Real World Evidence.
Conclusion: positive results solidify the growing impact of CareAcross’ solutions
The positive results of one of our randomised controlled trials, presented at the largest oncology congress worldwide, provide further evidence for the company’s solutions. We will keep evolving our systems to deliver even more value to patients and caregivers, as well as to healthcare professionals (through our Remote Patient Monitoring system).
You can read the abstract here.
Acknowledgements
CareAcross would like to acknowledge HeCOG as the leading partner in this study, recognise the important help of healthcare professionals, as well as the funding this study received from the Stavros Niarchos Foundation.
Most of all, we are all indebted to the cancer patients who participated in this clinical trial, despite their challenging diagnosis. We are deeply grateful to these 200 patients and their caregivers.